Ceapro Presents Unique Advantages of Its Disruptive Pressurized Gas Expanded Technology (PGX) at 2015 Composites at Lake Louise
EDMONTON, ALBERTA -- (Marketwired) -- 11/10/15 -- Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced that Bernhard Seifried, Ph.D., Ceapro's Senior Research Scientist and a co-inventor of its proprietary Pressurized Gas Expanded Technology (PGX) will present this morning at the prestigious 2015 Composites at Lake Louise engineering conference.
Dr. Seifried will make a podium presentation entitled, "PGX - Technology: A versatile technology for generating advanced biopolymer materials," which will feature the unique advantages of Ceapro's enabling technology for processing aqueous solutions or dispersions of high molecular weight biopolymers, such as starch, polysaccharides, gums, pectins or cellulose nanocrystals, into open-porous morphologies, consisting of nano-scale particles and pores.
Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "Our disruptive PGX enabling technology facilitates biopolymer processing at a new level for generating unique highly porous biopolymer morphologies that can be impregnated with bioactives/APIs or functionalized with other biopolymers to generate exfoliated nano-composites and novel advanced material. We believe this technology will provide transformational solutions not only for our internal programs, but importantly, can be applied much more broadly for Companies with whom we intend to partner globally."
Utilizing its PGX technology, Ceapro successfully produces its bioactive pharmaceutical grade powder formulation of beta glucan, which is an ingredient in a number of personal care cosmeceutical products as well as a therapeutic agent used for wound healing and a lubricative agent integrated into injectable systems used to treat conditions like urinary incontinence. The Company is developing its enabling PGX platform at the commercial scale level. In order to fully exploit the use of this innovative technology, Ceapro has recently decided to further expand its new world-class manufacturing facility by 10,000 square feet.
"The PGX platform generates unique morphologies that are not possible to produce with other conventional drying systems," Mr. Gagnon continued. "The ultra-light, highly porous polymer structures produced with PGX have a huge potential for use in an abundant number of applications ranging from functional foods, nutraceuticals, drug delivery and cosmeceuticals, to advanced technical applications."
Ceapro's novel PGX Technology can be utilized for a wide variety of bio-industrial processing applications including:
- Dry aqueous solutions or dispersions of polymers derived from agricultural and/or forestry feedstock, such as polysaccharides, gums, biopolymers at mild processing conditions (40°C).
- Purify biopolymers by removing lipids, salts, sugars and other contaminants, impurities and odours during the precipitation and drying process.
- Micronize the polymer to a matrix consisting of highly porous fibrils or spherical particles having nano-scale features depending on polymer molecular structure.
- Functionalize the polymer matrix by generating exfoliated nano-composites of various polymers forming fibers and/or spheres simply by mixing various aqueous polymer solutions/dispersions prior to PGX processing.
- Impregnate the polymer matrix homogeneously with thermo-sensitive bioactives and/or hydrophobic modifiers to tune solubility of the final polymer bioactive matrix all in the same processing equipment at mild conditions (40°C).
- Extract valuable bioactives at mild conditions from fermentation slurries, while drying the residual biomass.
The highly tune-able PGX process can generate exfoliated nano-composites and highly porous morphologies ranging from sub-micron particles (50nm) to micron-sized granules (2mm), as well as micro- and nanofibrils, granules, fine powders and aerogels with porosities of >99% and specific surface areas exceeding 300 m2/gram. The technology is based on a spray drying method, operating at mild temperatures (40°C) and moderate pressures (100-200 bar) utilizing PGX liquids, which is comprised of a mixture of food grade, recyclable solvents, generally regarded as safe (GRAS), such as pressurized carbon dioxide and anhydrous ethanol. The unique properties of PGX liquids afford single phase conditions and very low or vanishing interfacial tension during the spraying process. This then allows the generation of extremely fine particle morphologies with high porosity and a large specific surface area resulting in favorable solubilisation properties. This platform drying technology has been successfully scaled up from lab scale to pilot scale with a processing capacity of about 200 kg/hr of aqueous solutions.
About Composites at Lake Louise
Composites at Lake Louise (CALL) brings together researchers in structural, functional and biological materials. This prestigious by invitation only event is specifically designed to foster exchanges between scientists from academia, government and industry - and across disciplines of emphasis.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor and Media Contact:
Jenene Thomas Communications, LLC
T (US): 908-938-1475
Source: Ceapro Inc.
Released November 10, 2015